Lyell Immunopharma, Inc.
LYEL
$12.90
$0.201.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.00K | 6.00K | 15.00K | 8.00K | 7.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.00K | 6.00K | 15.00K | 8.00K | 7.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.00K | 6.00K | 15.00K | 8.00K | 7.00K |
| SG&A Expenses | 9.56M | 10.62M | 10.69M | 9.79M | 14.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.90M | -1.33M | -1.59M | -1.34M | -1.41M |
| Total Operating Expenses | 44.26M | 61.48M | 37.27M | 43.31M | 56.08M |
| Operating Income | -44.26M | -61.48M | -37.25M | -43.30M | -56.08M |
| Income Before Tax | -24.15M | -140.72M | -38.85M | -42.68M | -52.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.15M | -140.72M | -38.85M | -42.68M | -52.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.15M | -140.72M | -38.85M | -42.68M | -52.20M |
| EBIT | -44.26M | -61.48M | -37.25M | -43.30M | -56.08M |
| EBITDA | -41.93M | -59.08M | -34.69M | -40.16M | -52.64M |
| EPS Basic | -1.10 | -6.86 | -2.13 | -2.89 | -3.54 |
| Normalized Basic EPS | -0.69 | -2.32 | -1.33 | -1.64 | -2.16 |
| EPS Diluted | -1.10 | -6.86 | -2.13 | -2.89 | -3.54 |
| Normalized Diluted EPS | -0.69 | -2.32 | -1.33 | -1.64 | -2.16 |
| Average Basic Shares Outstanding | 21.88M | 20.52M | 18.27M | 14.79M | 14.76M |
| Average Diluted Shares Outstanding | 21.88M | 20.52M | 18.27M | 14.79M | 14.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |